Harrow (HROW) Non Operating Investment Income (2017 - 2024)
Harrow (HROW) posted Non Operating Investment Income of -$1.9 million for Q2 2024, down 54.09% on a QoQ basis from -$1.2 million in Q1 2024, and down 169.33% year-over-year from $2.8 million in Q3 2023.
Analysis
Harrow (HROW) Non Operating Investment Income (2017 - 2024) Analysis & Trends
Harrow has reported Non Operating Investment Income for 8 years, with the latest figure at -$1.9 million in Q2 2024.
- On a quarterly basis, Non Operating Investment Income fell 169.33% year-over-year to -$1.9 million in Q2 2024; TTM through Dec 2024 was -$3.2 million, a 202.55% decrease from a year earlier, with the FY2024 full-year figure at -$3.2 million, down 202.55% from the prior year.
- Non Operating Investment Income was -$1.9 million for Q2 2024 at Harrow, down from -$1.2 million in the prior quarter.
- The five-year high for Non Operating Investment Income was $8.6 million in Q3 2020, with the low at -$10.8 million in Q1 2020.
- Average Non Operating Investment Income over 5 years is -$1.1 million, with a median of -$1.1 million recorded in 2022.
- The sharpest annual moves came in 2020 and 2023: Non Operating Investment Income sank 1332.29% in 2020, then soared 1369.06% in 2023.
- Over 5 years, Non Operating Investment Income stood at $805000.0 in 2020, then plunged by 284.72% to -$1.5 million in 2021, then surged by 195.97% to $1.4 million in 2022, then slumped by 70.85% to $416000.0 in 2023, then plunged by 562.26% to -$1.9 million in 2024.
- The last three Non Operating Investment Income figures came in at -$1.9 million (Q2 2024), -$1.2 million (Q1 2024), and $416000.0 (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn | - |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - | - |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn | 9.81 Mn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | - |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 50.36 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Dec 31, 2023 | 416,000.00 |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | -714,000.00 |
| Mar 31, 2023 | 2.04 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | 139,000.00 |
| Dec 31, 2021 | -1.49 Mn |
| Sep 30, 2021 | -2.22 Mn |
| Jun 30, 2021 | -3.58 Mn |
| Mar 31, 2021 | -2.84 Mn |
| Dec 31, 2020 | 805,000.00 |
| Sep 30, 2020 | 8.58 Mn |
| Jun 30, 2020 | -5.01 Mn |
| Mar 31, 2020 | -10.85 Mn |
| Dec 31, 2019 | -549,000.00 |
| Sep 30, 2019 | -5.53 Mn |